Boston Scientific Corporation (NYSE:BSX) Shares Purchased by IFM Investors Pty Ltd

IFM Investors Pty Ltd boosted its stake in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 8.7% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 309,327 shares of the medical equipment provider's stock after purchasing an additional 24,762 shares during the quarter. IFM Investors Pty Ltd's holdings in Boston Scientific were worth $31,205,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently added to or reduced their stakes in BSX. Norges Bank bought a new stake in Boston Scientific during the fourth quarter valued at about $1,762,522,000. Capital World Investors boosted its holdings in Boston Scientific by 28.7% in the fourth quarter. Capital World Investors now owns 27,899,903 shares of the medical equipment provider's stock worth $2,492,041,000 after acquiring an additional 6,216,199 shares in the last quarter. Wellington Management Group LLP boosted its holdings in Boston Scientific by 10.2% in the fourth quarter. Wellington Management Group LLP now owns 36,165,399 shares of the medical equipment provider's stock worth $3,230,293,000 after acquiring an additional 3,344,571 shares in the last quarter. GAMMA Investing LLC boosted its holdings in Boston Scientific by 11,720.3% in the first quarter. GAMMA Investing LLC now owns 2,577,887 shares of the medical equipment provider's stock worth $260,057,000 after acquiring an additional 2,556,078 shares in the last quarter. Finally, Axiom Investors LLC DE boosted its holdings in Boston Scientific by 208.2% in the fourth quarter. Axiom Investors LLC DE now owns 3,752,430 shares of the medical equipment provider's stock worth $335,167,000 after acquiring an additional 2,535,007 shares in the last quarter. Institutional investors own 89.07% of the company's stock.

Boston Scientific Stock Performance

NYSE:BSX traded up $0.67 during trading hours on Friday, reaching $104.30. The company had a trading volume of 2,931,148 shares, compared to its average volume of 6,666,246. Boston Scientific Corporation has a 1-year low of $71.88 and a 1-year high of $107.53. The firm has a market cap of $154.30 billion, a PE ratio of 76.13, a price-to-earnings-growth ratio of 2.71 and a beta of 0.68. The business's 50 day moving average price is $103.42 and its 200-day moving average price is $100.14. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.45 and a quick ratio of 0.88.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings data on Wednesday, April 23rd. The medical equipment provider reported $0.75 EPS for the quarter, beating analysts' consensus estimates of $0.67 by $0.08. The business had revenue of $4.66 billion during the quarter, compared to analysts' expectations of $4.57 billion. Boston Scientific had a return on equity of 18.67% and a net margin of 11.58%. The business's revenue was up 20.9% compared to the same quarter last year. During the same period in the previous year, the business earned $0.56 earnings per share. Research analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current year.

Analyst Ratings Changes

Several brokerages have weighed in on BSX. Evercore ISI raised their price target on Boston Scientific from $110.00 to $112.00 and gave the stock an "outperform" rating in a report on Thursday, April 24th. Citigroup reissued a "buy" rating and issued a $125.00 price target (up previously from $119.00) on shares of Boston Scientific in a report on Thursday, May 22nd. Morgan Stanley raised their price target on Boston Scientific from $120.00 to $125.00 and gave the stock an "overweight" rating in a report on Friday, May 16th. Royal Bank Of Canada raised their price target on Boston Scientific from $116.00 to $120.00 and gave the stock an "outperform" rating in a report on Thursday, April 24th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $115.00 price target on shares of Boston Scientific in a report on Wednesday, May 28th. Twenty-two analysts have rated the stock with a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat.com, Boston Scientific currently has an average rating of "Buy" and an average price target of $116.09.

Insider Buying and Selling at Boston Scientific

In other news, SVP Vance R. Brown sold 4,826 shares of the company's stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $95.09, for a total transaction of $458,904.34. Following the completion of the transaction, the senior vice president directly owned 36,193 shares of the company's stock, valued at $3,441,592.37. This represents a 11.77% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP John Bradley Sorenson sold 4,572 shares of the company's stock in a transaction that occurred on Monday, May 5th. The stock was sold at an average price of $104.54, for a total value of $477,956.88. Following the transaction, the executive vice president directly owned 18,705 shares of the company's stock, valued at approximately $1,955,420.70. The trade was a 19.64% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 461,970 shares of company stock worth $47,755,193. 0.50% of the stock is currently owned by corporate insiders.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.